Human hematopoietic cells for gene therapy

Roland Jurecic, John W. Belmont

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The bone marrow has been considered a key target tissue from the earliest days of gene therapy research. 1 Experience with bone marrow transplantation demonstrated that within the adult marrow there are cells capable of completely and permanently reconstituting the entire blood and immune systems. Progress in the understanding of human hematologic diseases at the molecular level, development of gene transfer technology, and increasing experience in isolation, ex vivo manipulation, and transplantation of primitive hematopoietic cells all contribute to continued interest in gene transfer into hematopoietic stem cells. 2 – 7 Initial efforts to introduce genes into blood cells were frustrated by the poor efficiency of gene transfer and uncertainties about safety. 8, 9 Two paths of investigation have drastically improved the long-term prospects of stem cell gene therapy. The first is the development of viral vectors capable of integrating DNA stably into target cells. Stable integration appears to be necessary in this system because of the extensive cell proliferation (up to 50 cell doublings) that takes place between the stem cell and the development of terminally differentiated blood cells. The demonstration of retroviral vector transduction of murine hematopoietic progenitors provided the starting point for numerous preclinical models of stem cell gene therapy. 10 A second important contribution has come from studies addressing stem cell phenotype, their enumeration and enrichment, ex vivo maintenance, and developmental capacity after transplantation.

Original languageEnglish (US)
Title of host publicationSomatic Gene Therapy
PublisherCRC Press
Pages7-30
Number of pages24
ISBN (Electronic)9781351085212
ISBN (Print)9781315897660
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Gene therapy
Cell- and Tissue-Based Therapy
Stem cells
Genetic Therapy
Gene transfer
Stem Cells
Blood
Genes
Blood Cells
Transplantation
Bone Marrow
Technology Transfer
Bone
Cells
Hematologic Diseases
Hematopoietic Stem Cells
Bone Marrow Transplantation
Immune system
Uncertainty
Cell proliferation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Jurecic, R., & Belmont, J. W. (2018). Human hematopoietic cells for gene therapy. In Somatic Gene Therapy (pp. 7-30). CRC Press. https://doi.org/10.1201/9781351076760

Human hematopoietic cells for gene therapy. / Jurecic, Roland; Belmont, John W.

Somatic Gene Therapy. CRC Press, 2018. p. 7-30.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jurecic, R & Belmont, JW 2018, Human hematopoietic cells for gene therapy. in Somatic Gene Therapy. CRC Press, pp. 7-30. https://doi.org/10.1201/9781351076760
Jurecic R, Belmont JW. Human hematopoietic cells for gene therapy. In Somatic Gene Therapy. CRC Press. 2018. p. 7-30 https://doi.org/10.1201/9781351076760
Jurecic, Roland ; Belmont, John W. / Human hematopoietic cells for gene therapy. Somatic Gene Therapy. CRC Press, 2018. pp. 7-30
@inbook{2553f0d1815f423ebe8979ec1922b01a,
title = "Human hematopoietic cells for gene therapy",
abstract = "The bone marrow has been considered a key target tissue from the earliest days of gene therapy research. 1 Experience with bone marrow transplantation demonstrated that within the adult marrow there are cells capable of completely and permanently reconstituting the entire blood and immune systems. Progress in the understanding of human hematologic diseases at the molecular level, development of gene transfer technology, and increasing experience in isolation, ex vivo manipulation, and transplantation of primitive hematopoietic cells all contribute to continued interest in gene transfer into hematopoietic stem cells. 2 – 7 Initial efforts to introduce genes into blood cells were frustrated by the poor efficiency of gene transfer and uncertainties about safety. 8, 9 Two paths of investigation have drastically improved the long-term prospects of stem cell gene therapy. The first is the development of viral vectors capable of integrating DNA stably into target cells. Stable integration appears to be necessary in this system because of the extensive cell proliferation (up to 50 cell doublings) that takes place between the stem cell and the development of terminally differentiated blood cells. The demonstration of retroviral vector transduction of murine hematopoietic progenitors provided the starting point for numerous preclinical models of stem cell gene therapy. 10 A second important contribution has come from studies addressing stem cell phenotype, their enumeration and enrichment, ex vivo maintenance, and developmental capacity after transplantation.",
author = "Roland Jurecic and Belmont, {John W.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1201/9781351076760",
language = "English (US)",
isbn = "9781315897660",
pages = "7--30",
booktitle = "Somatic Gene Therapy",
publisher = "CRC Press",

}

TY - CHAP

T1 - Human hematopoietic cells for gene therapy

AU - Jurecic, Roland

AU - Belmont, John W.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The bone marrow has been considered a key target tissue from the earliest days of gene therapy research. 1 Experience with bone marrow transplantation demonstrated that within the adult marrow there are cells capable of completely and permanently reconstituting the entire blood and immune systems. Progress in the understanding of human hematologic diseases at the molecular level, development of gene transfer technology, and increasing experience in isolation, ex vivo manipulation, and transplantation of primitive hematopoietic cells all contribute to continued interest in gene transfer into hematopoietic stem cells. 2 – 7 Initial efforts to introduce genes into blood cells were frustrated by the poor efficiency of gene transfer and uncertainties about safety. 8, 9 Two paths of investigation have drastically improved the long-term prospects of stem cell gene therapy. The first is the development of viral vectors capable of integrating DNA stably into target cells. Stable integration appears to be necessary in this system because of the extensive cell proliferation (up to 50 cell doublings) that takes place between the stem cell and the development of terminally differentiated blood cells. The demonstration of retroviral vector transduction of murine hematopoietic progenitors provided the starting point for numerous preclinical models of stem cell gene therapy. 10 A second important contribution has come from studies addressing stem cell phenotype, their enumeration and enrichment, ex vivo maintenance, and developmental capacity after transplantation.

AB - The bone marrow has been considered a key target tissue from the earliest days of gene therapy research. 1 Experience with bone marrow transplantation demonstrated that within the adult marrow there are cells capable of completely and permanently reconstituting the entire blood and immune systems. Progress in the understanding of human hematologic diseases at the molecular level, development of gene transfer technology, and increasing experience in isolation, ex vivo manipulation, and transplantation of primitive hematopoietic cells all contribute to continued interest in gene transfer into hematopoietic stem cells. 2 – 7 Initial efforts to introduce genes into blood cells were frustrated by the poor efficiency of gene transfer and uncertainties about safety. 8, 9 Two paths of investigation have drastically improved the long-term prospects of stem cell gene therapy. The first is the development of viral vectors capable of integrating DNA stably into target cells. Stable integration appears to be necessary in this system because of the extensive cell proliferation (up to 50 cell doublings) that takes place between the stem cell and the development of terminally differentiated blood cells. The demonstration of retroviral vector transduction of murine hematopoietic progenitors provided the starting point for numerous preclinical models of stem cell gene therapy. 10 A second important contribution has come from studies addressing stem cell phenotype, their enumeration and enrichment, ex vivo maintenance, and developmental capacity after transplantation.

UR - http://www.scopus.com/inward/record.url?scp=85052859714&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052859714&partnerID=8YFLogxK

U2 - 10.1201/9781351076760

DO - 10.1201/9781351076760

M3 - Chapter

AN - SCOPUS:85052859714

SN - 9781315897660

SP - 7

EP - 30

BT - Somatic Gene Therapy

PB - CRC Press

ER -